sandoz
Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.
Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.
FDA Issues Boxed Warning for Anaphylaxis Risk with Multiple Sclerosis Drugs Copaxone and Glatopa
FDA, boxed warning, anaphylaxis, multiple sclerosis, Copaxone, Glatopa, glatiramer acetate, Teva, Sandoz
Sandoz Reaches $275 Million Settlement in US Generic Drug Price Fixing Case
Sandoz, generic drug price fixing, settlement, antitrust litigation, pharmaceutical industry
GSK to Close UK Antibiotic Factory in Ulverston Following Sandoz Contract Termination
GSK, Ulverston, antibiotic factory, Sandoz contract, closure, job losses
Regeneron Takes Legal Action Against Sandoz to Block Eylea Biosimilar
Regeneron, Sandoz, Eylea, biosimilar, lawsuit, patent infringement
FDA Approves Sandoz and Ascendis Pharma’s Treatments for nAMD and Hypoparathyroidism
FDA approval, Sandoz, Ascendis Pharma, nAMD, hypoparathyroidism, Yorvipath, TransCon PTH
Ex-Pharmaceutical Executive Receives Probation in Antitrust Violation Case
Pharmaceutical industry, antitrust violation, price-fixing, Sandoz, executive, sentencing, probation
Sandoz Wins Historic FDA Approval for First Two Interchangeable Denosumab Biosimilars Targeting Amgen’s Blockbuster Bone Therapy
Sandoz, FDA approval, Denosumab biosimilars, Wyost, Jubbonti, Interchangeable, Prolia, Xgeva, Amgen, Osteoporosis, Bone metastases, Cancer-related skeletal events, Patent litigation
Sandoz Pays $265 Million to Resolve Partial Antitrust Claims in Price Fixing Lawsuits
sandoz, Settlement and Resettlement, Litigation